Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 78Sarcoma 4Other neoplasm 3Endocrine 3Thoracic 2NET 2CNS 2Tumor-Agnostic 1Head & Neck 1Breast 1

Conditions

Rectal Neuroendocrine Tumors 1Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 48Everolimus 40Magnetic Resonance Spectroscopy 21lanreotide 17Temozolomide 17gallium Ga 68 dotatate 15Octreotide 15pembrolizumab 13Nivolumab 13surufatinib 12Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11Sunitinib 10pasireotide 9Specimen Handling 9Positron Emission Tomography Computed Tomography 9Lutetium-177 93-Iodobenzylguanidine 9Ga(III)-DOTATOC 8Carboplatin 8telotristat ethyl 6copper dotatate CU-64 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Ipilimumab 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endoscopic Mucosal Resection × NET × Clear all
NCT07373015 2026-01-28

Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase NA Not yet recruiting
118 enrolled
EndocrineGastrointestinalNET

Rectal Neuroendocrine Tumors

NCT06121752 2024-10-15

DNET

Asian Institute of Gastroenterology, India

Phase NA Unknown
54 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡